Abstract: Compounds of formula (I): ##STR1## wherein the substituents are as defined herein, are antiparasitic agents.

Abstract: A compound of the formula I ##STR1## or a pharmaceutically acceptable salt or hydrate thereof, wherein X, Y, Z and R.sup.1 to R.sup.7 are as defined herein, are inhibitors of H. pylori and therefore of use in the treatment and prevention of peptic ulcers, gastritis, dyspepsia, and gastric cancer.

Abstract: The R(+) isomer of amlodipine is a potent inhibitor of smooth muscle cell migration despite its lack of calcium channel-blocking activity. It is useful for treating atherosclerosis, re-stenosis after angioplasty and endometriosis.

Abstract: The invention relates to a monohydrate polymorph PII.M of a compound of the formula ##STR1## exhibiting the following X-ray powder diffraction pattern______________________________________ Peak No. 1 2 3 4 5 6 7 8 ______________________________________ 2.sub.-- .theta..sub.-- (.degree.) Cu 3.6 7.3 13.7 14.5 17.1 21.) 23.6 26.7 d space 24.2 12.2 6.5 6.1 5.2 4.2 3.8 3.3 ______________________________________The invention also relates to methods of preparing the above compound, pharmaceutical compositions containing the above compound, and methods of treating bacterial infections by administering the above compound.

Abstract: The present invention relates to compounds of formula 1 ##STR1## and to pharmaceutically acceptable salts and solvates thereof, wherein Z, R, R.sup.3 and R.sup.4 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering the compounds of formula 1 to said mammal.

Abstract: Compounds of formula (I) or salts thereof: ##STR1## wherein R.sup.1 is hydrogen, methoxy or formamido; R.sup.2 is an acyl group; CO.sub.2 R.sup.3 is a carboxy group or a carboxylate anion, or R.sup.3 is a carboxy protecting group, pharmaceutically acceptable salt-forming group or in vivo hydrolysable ester group; R.sup.4 represents hydrogen or up to four substituents; X is O, S, SO or SO.sub.2 ; Y is O, S, SO or SO.sub.2 ; n is 0 or 1; and m is 1 or 2. The compounds have antibacterial activity. Methods of synthesis of, and pharmaceutical formulations containing, compounds (I) are also described.

Abstract: An apparatus for directing the flow of air in a laboratory-type hood. A laboratory hood is provided with a closure sash and the lower edge of the closure sash has an airfoil that extends into the laboratory hood work space.

Abstract: A compound of the formula ##STR1## wherein n, X, Y and Ar are as defined herein, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.

Abstract: Compositions of matter comprising droloxifene or a pharmaceutically acceptable salt thereof and a cyclodextrin. Preferred cyclodextrins are SBECD and HPBCD. The composition can comprise a dry mixture, a dry inclusion complex or an aqueous solution. The citrate salt of droloxifene is preferred.

Abstract: A compound of formula (II) or a salt: ##STR1##

Abstract: Compounds of formula (IA) and (IB), ##STR1## wherein the substituents are as defined herein, and the salts and solvates thereof, are useful as antiparasitic agents.

Abstract: Processes for preparing spirolaxine and spirolaxine methyl ether, the compounds of formulas (I) and (II) respectively, ##STR1## comprising fermenting fungi selected from the group consisting of Sporotrichum pruinosum FD 29585, ATCC 74327; Sporotrichum pruinosum FD 29454, ATCC 74329; Sporotrichun pruinosum FD 29586, ATCC 74328; and Phanerochaete chrysosporiun LN 3576, ATCC 74326. This invention also relates to a process for preparing spirolaxine comprising fermenting Sporotrichum pruinosum FD 29458, ATCC 74330.

Abstract: Compounds of formula (I) or pharmaceutically, veterinarily or agriculturally acceptable salts thereof, or pharmaceutically, veterinarily or agriculturally acceptable solvates of either entity, wherein R.sup.1 is 2,4,6-trisubstituted phenyl or 3,5-disubstituted pyridin-2-yl; R.sup.3 is C.sub.1 -C.sub.4 alkyl optionally substituted with hydroxy or with one or more halo; cyano, C.sub.1 to C.sub.5 alkanoyl or phenyl; R.sup.5 is hydrogen, C.sub.1 to C.sub.4 alkyl, amino or halo; R.sup.2 and R.sup.4 are each independently selected from hydrogen, C.sub.1 to C.sub.4 alkyl, fluoro, chloro and bromo or, together with the carbon atom to which they are attached, form a C.sub.3 to C.sub.6 cycloalkyl group; R.sup.6 and R.sup.8 are each independently selected from hydrogen, C.sub.1 to C.sub.4 alkyl, fluoro, chloro and bromo; or, when R.sup.2 and R.sup.4 do not form part of a cycloalkyl group, R.sup.2 and R.sup.6, together with the carbon atoms to which they are attached, may form a C.sub.5 to C.sub.

Abstract: A method for preventing canine coronavirus in dogs is disclosed which comprises administering to a dog a live or inactivated vaccine prepared from transmissible gastroenteritis virus of swine (a TGEV vaccine). An inactivated vaccine composition for use in such a method and a process for the manufacture of the inactivated vaccine composition are described.

Abstract: A compound of the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein X, O R, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are defined in the specification; compositions containing such compounds; intermediates used in the preparation of such compounds; and methods for treating a disease associated with the altered tone and/or motility of smooth muscle, for example chronic obstructive airways disease, asthma, urinary incontinence, irritable bowel syndrome, diverticular disease, oesophageal achalasia, and hypertension.

Abstract: The present invention relates to compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering the compounds of formula I to said mammal.

Abstract: A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.

Abstract: A new group of parasiticidal pyrazole derivatives has now been found.

Abstract: A method of treating atherosclerosis, independent of lipid lowering, in mammals, induding humans, in need of treatment by inhibiting progression of an atherogenic lesion or by stabilizing plaque. Such lesion progression inhibition or plaque stabilization is preferably achieved by directly inhibiting chemokine expression leading to excessive inflammatory cell recruitment by administering certain estrogen agonist/antagonists.

Abstract: The invention relates to a non-hygroscopic polymorph of the following compound ##STR1## and to pharmaceutical compositions containing the above compound, methods of treating bacterial infections by administering the above compound, and to methods of preparing the above compound and related compounds.